SG64897A1 - Composition and method of treating hepatitis c - Google Patents

Composition and method of treating hepatitis c

Info

Publication number
SG64897A1
SG64897A1 SG1996006295A SG1996006295A SG64897A1 SG 64897 A1 SG64897 A1 SG 64897A1 SG 1996006295 A SG1996006295 A SG 1996006295A SG 1996006295 A SG1996006295 A SG 1996006295A SG 64897 A1 SG64897 A1 SG 64897A1
Authority
SG
Singapore
Prior art keywords
thymosin
composition
treating hepatitis
immune system
potentiating
Prior art date
Application number
SG1996006295A
Other languages
English (en)
Inventor
Paul Chretien
Milton Mutchnick
Original Assignee
Alpha 1 Biomedicals Inc
Milton Mutchnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Milton Mutchnick filed Critical Alpha 1 Biomedicals Inc
Publication of SG64897A1 publication Critical patent/SG64897A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
SG1996006295A 1991-09-13 1992-09-08 Composition and method of treating hepatitis c SG64897A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
SG64897A1 true SG64897A1 (en) 1999-05-25

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996006295A SG64897A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Country Status (23)

Country Link
US (3) US6001799A (hu)
EP (1) EP0603305B1 (hu)
JP (1) JP3228512B2 (hu)
KR (1) KR100254082B1 (hu)
AT (1) ATE152914T1 (hu)
AU (1) AU667327B2 (hu)
CA (1) CA2119006C (hu)
CZ (1) CZ286827B6 (hu)
DE (1) DE69219782T2 (hu)
DK (1) DK0603305T3 (hu)
ES (1) ES2103966T3 (hu)
FI (1) FI107879B (hu)
GR (1) GR3024025T3 (hu)
HK (1) HK1021687A1 (hu)
HU (1) HU221006B1 (hu)
MX (1) MX9205240A (hu)
NO (1) NO941310D0 (hu)
RO (1) RO111991B1 (hu)
RU (1) RU2104010C1 (hu)
SG (1) SG64897A1 (hu)
TW (1) TW224053B (hu)
WO (1) WO1993005806A1 (hu)
ZA (1) ZA926964B (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (hu) * 1991-09-13 1994-05-21 Paul B Chretien
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU4671193A (en) * 1992-07-13 1994-01-31 Kenneth E. Sherman Composition and method of treating hepatitis b
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
CA2175337C (en) * 1993-11-05 2000-06-20 Paul B. Chretien Method and composition for treatment of patients having decompensated liver disease
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
ATE205397T1 (de) * 1996-02-28 2001-09-15 Unihart Corp Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
DK1311279T3 (da) * 2000-08-07 2007-02-12 Sciclone Pharmaceuticals Inc Behandling af hepatitis C med thymosin, interferon og ribavirin
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
CA2460341A1 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
DK1448223T3 (da) 2001-10-26 2008-02-18 Rhode Island Hospital Thymosin-forögelse af genetisk immunisering
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
KR20040094692A (ko) * 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
DE602004027127D1 (de) * 2003-03-28 2010-06-24 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
UA80870C2 (en) * 2003-03-28 2007-11-12 Sciclone Pharmaceuticals Inc Method for treatment or prevention of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
WO2005003147A2 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2005009418A2 (en) * 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
SI3109244T1 (sl) 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20110195048A1 (en) * 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (hu) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
CA2119006C (en) 2005-08-23
AU2644792A (en) 1993-04-27
FI941133A (fi) 1994-03-10
HU221006B1 (hu) 2002-07-29
CZ286827B6 (cs) 2000-07-12
FI941133A0 (fi) 1994-03-10
HU9400758D0 (en) 1994-06-28
JP3228512B2 (ja) 2001-11-12
US5849696A (en) 1998-12-15
CA2119006A1 (en) 1993-04-01
NO941310L (no) 1994-04-12
EP0603305A1 (en) 1994-06-29
US6001799A (en) 1999-12-14
TW224053B (hu) 1994-05-21
HK1021687A1 (en) 2000-06-23
DK0603305T3 (da) 1997-09-01
GR3024025T3 (en) 1997-10-31
CZ55194A3 (en) 1994-10-19
DE69219782T2 (de) 1997-10-09
MX9205240A (es) 1993-07-01
RU94022480A (ru) 1996-07-20
ZA926964B (en) 1993-04-26
US20070218033A1 (en) 2007-09-20
RU2104010C1 (ru) 1998-02-10
JPH06510998A (ja) 1994-12-08
NO941310D0 (no) 1994-04-12
DE69219782D1 (de) 1997-06-19
ES2103966T3 (es) 1997-10-01
KR100254082B1 (ko) 2000-09-01
ATE152914T1 (de) 1997-05-15
WO1993005806A1 (en) 1993-04-01
EP0603305B1 (en) 1997-05-14
HUT75166A (en) 1997-04-28
AU667327B2 (en) 1996-03-21
RO111991B1 (ro) 1997-04-30
FI107879B (fi) 2001-10-31

Similar Documents

Publication Publication Date Title
GR3024025T3 (en) Composition and method of treating hepatitis c.
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
GB2282811B (en) Vaccine for the prevention of porcine reproductive and respiratory syndrome
GR3022969T3 (en) Products for the treatment of endotoxic shock in a mammal
EP0589237A3 (en) Vacuum etching apparatus and method for processing its parts.
DE69312312D1 (de) Mit kautschuk modifizierte polylactid- und/oder glycolidzusammensetzung
PL297849A1 (en) Vaccine against and method of treating the patients infectedwith hiv virus
EP0579453A3 (en) Composition for masonry treatment and process.
ZA89915B (en) Method and composition for accelerating the hardening of cements and removing efflorescent effects
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
EP0627930A4 (en) COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
DE3685484D1 (hu)
EP0610444A4 (en) METHOD OF TREATING VIRAL DISEASES.
ATE155345T1 (de) Gegengift immunsera
MY121198A (en) Method of treating hepatitis c in non-responders to interferon treatment.
EP0634440A3 (en) Method for curing organosiloxane compositions in the presence of cure inhibiting materials.
EP0452360A4 (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
MY110041A (en) Composition and method of treating hepatitis c
ZA947879B (en) Process for the preparation of cyclopentanone mono- or disubstituted in the 2-position
ZA897105B (en) Method and composition for the treatment of viral infections
BG98272A (en) Preparation and method for the treatment of virus hepatitis
EP0614364A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFECTIONS USING OPTICALLY PURE (S) -LOMEFLOXACIN.
GB9013938D0 (en) Vaccine and treatment for the prevention of type i or juvenile diabetes
WO1993009778A3 (en) Use of brl 38227 for the treatment and prophylaxis of hyperlipidemia